Clik here to view.
Insulet sales grow 22% in Q1
Insulet (NSDQ:PODD) topped estimates on Wall Street yesterday with its first-quarter results, topping analysts’ sales expectations by $1.9 million. The Billerica, Mass.-based company reeled in its...
View ArticleClik here to view.
FDA clears Insulet’s Omnipod Dash insulin management system
Insulet (NSDQ:PODD) said today that the FDA granted 510(k) clearance to its Omnipod Dash insulin management system. The system wirelessly connects the company’s Personal Diabetes Manager with its...
View ArticleClik here to view.
Closed-loop insulin delivery systems shine at annual diabetes meeting
As device-makers, healthcare practitioners and people with diabetes convened at this year’s annual meeting of the American Diabetes Association, one major theme emerged: the industry is catching on to...
View ArticleClik here to view.
Eli Lilly touts data for concentrated insulin delivered via Insulet’s Omnipod...
Eli Lilly (NYSE:LLY) touted data this week from a Phase III study evaluating its Humulin R U-500 concentrated insulin delivered via Insulet‘s (NSDQ:PODD) investigational Omnipod U-500 device. The...
View ArticleClik here to view.
Insulet assumes direct commercial operations in Europe
Insulet (NSDQ:PODD) said today that it has assumed direct commercial operations in Europe for its Omnipod tubeless insulin pump. The Billerica, Mass.-based company first announced it would part ways...
View ArticleClik here to view.
Insulet’s Omnipod nabs preferred insulin pump status in British Columbia
Insulet (NSDQ:PODD) said today that its Omnipod device was selected as the preferred insulin pump in British Columbia, Canada under the province’s expanded PharmaCare insulin pump program. According to...
View ArticleClik here to view.
Insulet extends deal with Glooko in Europe
Insulet (NSDQ:PODD) said today that it inked a deal with Glooko to connect data from Insulet’s Omnipod insulin delivery devices in Europe with the Glooko+diasend diabetes data management system. Glooko...
View ArticleClik here to view.
Insulet settles shareholder suit over Omnipod Eros device
Insulet (NSDQ:PODD) shareholders have agreed to settle a lawsuit alleging that the device-maker misrepresented the success of its Omnipod Eros roll-out in 2013. The financial details of the settlement...
View ArticleClik here to view.
Insulet slides on Q2 revenue miss
Insulet (NSDQ:PODD) shares took a hit today after the company reported second-quarter revenues that missed the consensus forecast and cut its outlook for the rest of the year. Billerica, Mass.-based...
View ArticleClik here to view.
How Insulet’s CEO plans to create a billion-dollar business
When Pat Sullivan joined Insulet (NSDQ:PODD) in 2014, the Billerica, Mass.-based company was reeling in roughly $300 million in revenue selling its Omnipod tubless insulin delivery system. Sullivan, a...
View ArticleClik here to view.
Insulet promotes COO to corner office as CEO Sullivan sets retirement date
Insulet (NSDQ:PODD) announced this week that president & COO Shacey Petrovic will succeed CEO Patrick Sullivan after he retires at the end of the year. Petrovic plans to stay on as president of the...
View ArticleClik here to view.
Europe OKs Novo Nordisk’s Fiasp for Insulet’s Omnipod
Insulet (NSDQ:PODD) said today that its Omnipod insulin management system is available in Europe for use with Novo Nordisk‘s (NYSE:NVO) Fiasp fast-acting insulin aspart. Novo Nordisk’s Fiasp product...
View ArticleClik here to view.
These 10 medtech companies care a lot about research
[Image from unsplash.com]These 10 medical device companies spent the largest portion of their budgets on research and development. Here’s a look at what they produced. Each year, Medical Design &...
View ArticleClik here to view.
Insulet Q3 beats The Street
Insulet (NSDQ:PODD) today posted third quarter earnings that beat expectations on Wall Street and lifted its guidance for the remaining year. The Billerica, Mass.-based company posted profits of $1.7...
View ArticleClik here to view.
Insulet inks deal with Samsung to develop smartphone-controlled Omnipod
Insulet (NSDQ:PODD) said this week that it inked a deal with Samsung to develop an Omnipod insulin delivery system that would allow users to control their insulin pump therapy with a Galaxy smartphone....
View ArticleClik here to view.
Insulet’s Omnipod Dash system lands ISO cert for data security
Insulet (NSDQ:PODD) said this week that it won ISO 27001 certification for its Omnipod Dash product, meeting the international standard for best practice in an information security management system....
View ArticleClik here to view.
10 of the best performing medical device stocks of 2018
(Image from Unsplash) Nearly half of the world’s 100 largest medical device companies saw their stock prices increase by double-digit percentages during the first 10 months of 2018, according to a...
View ArticleClik here to view.
Sanuwave confirms acting CEO Richardson as company head | Personnel Moves –...
Sanuwave said late last month that it lifted acting CEO and board chair Kevin Richardson to a permanent position in the corner office. Richardson joined the Suwanee, Ga.-based company in 2009 as board...
View ArticleClik here to view.
Tidepool raises $6m to develop automated insulin delivery app
Tidepool said this week that it raised $6 million from JDRF and the Leona M. & Harry B. Helmsley Charitable Trust to support the development of Tidepool Loop – a hybrid, closed-loop automated...
View ArticleClik here to view.
Making diabetes management simpler with a tubeless pump
People using traditional insulin pumps to manage their diabetes often have to adjust their daily lives to live comfortably with a tubed pump. Insulet wants to change that. For nearly three decades,...
View ArticleClik here to view.
Analyst downgrades pressure medtech stocks
Several medical device companies took hits yesterday after analysts on Wall Street downgraded their stocks, on a day when the major market indices each closed up a hair, and even medtech firms that...
View ArticleClik here to view.
Insulet taps former Medtronic finance exec McMillan as CFO | Personnel Moves...
Insulet (NSDQ:PODD) said yesterday that it tapped former Medtronic minimally invasive therapies CFO and finance VP Wayde McMillan as its new chief financial officer, replacing Michael Levitz. The...
View ArticleClik here to view.
Insulet president & CEO Shacey Petrovic to participate in keynote interview...
[Press Release] – WTWH Media and MassDevice.com announced today that Shacey Petrovic, president and CEO of Insulet (NSDQ:PODD), will be a featured keynote speaker at DeviceTalks Boston 2019....
View ArticleClik here to view.
Glooko, Novo Nordisk team up for connected insulin pens
Glooko announced this month that it’s teaming up to connect Novo Nordisk‘s (NYSE:NVO) insulin pens with the company’s diasend diabetes management solution. Novo Nordisk plans to launch its connected...
View ArticleClik here to view.
Insulet tops estimates with Q4 results
Insulet (NSDQ:PODD) posted its fourth-quarter and full-year financial results yesterday after the markets closed, beating estimates on Wall Street. The Acton, Mass.-based company posted profits of $9.9...
View Article
